Original from: Guardant Health
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (¡°Policlinico Gemelli¡±) to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health¡¯s cutting-edge proprietary digital sequencing platform, this initiative will include on-site analysis of Guardant360 ® CDx liquid biopsy tests directly within the Policlinico Gemelli facilities in Rome, Italy.
The partnership will serve clinical research and patient care needs, marking a significant milestone as one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. This collaboration underscores Guardant Health¡¯s commitment to expanding access to innovative cancer diagnostics and improving patient outcomes globally. Policlinico Gemelli, one of Italy¡¯s largest and most renowned hospitals, serves thousands of cancer patients each year at its comprehensive cancer center. The facility is known for its advanced oncology services, including diagnostics, treatment, and research.
¡°Gemelli, one of the most important Italian and European oncology centers, can now offer its patients more state-of-the-art diagnostics for precision oncology through this innovative test. This partnership with Guardant Health represents a fundamental step for our hospital,¡± said Professor Giovanni Scambia, Scientific Director of Policlinico Gemelli.
In Italy, approximately 400,000 new malignant tumor cases are recorded annually. The average of annual deaths caused by tumors, according to the Italian Cancer Registers, is about 3.5 deaths and about 2.5 per 1,000 men and women, respectively, for a total of about three deaths every 1,000 people. 1 Guardant Health¡¯s tests are used by oncologists worldwide to guide treatment decisions across solid tumor cancers and by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development.
In 2024, Guardant Health announced certification for its Guardant360® CDx blood test under the European Union¡¯s In Vitro Diagnostic Regulation (IVDR 2017/746). The certification from TÜV SÜD Product Service is for tumor mutation profiling in patients with any solid cancerous tumor and for companion diagnostic indications to identify patients who may benefit from certain targeted therapies for advanced non-small cell lung cancer and breast cancer.
¡°We¡¯re thrilled to partner with Policlinico Gemelli, empowering clinicians to swiftly detect tumor alterations with a blood test, guiding personalized treatments, and fueling research innovation. This collaboration brings us closer to our mission of ensuring all cancer patients worldwide have access to the latest advancements for optimal care,¡± said Helmy Eltoukhy, Guardant Health Co-CEO.
